

# South & Central America T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

<https://marketpublishers.com/r/S317869E9B2CEN.html>

Date: January 2024

Pages: 55

Price: US\$ 3,550.00 (Single User License)

ID: S317869E9B2CEN

## Abstracts

The South & Central America T cell therapy market was valued at US\$ 84.11 million in 2022 and is expected to reach US\$ 265.59 million by 2030; it is estimated to grow at a CAGR of 15.5% from 2022 to 2030.

Increasing Number of T-Cell Therapy Approvals Fuels the South & Central America T Cell Therapy Market

Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of t cell therapy. Globally, cell therapies are widely adopted owing to the availability of various approval:

- In 2023: Kite, a Gilead Company announced launching operations in Saudi Arabia, Singapore, and Brazil as part of its commercial expansion. Kite has filed regulatory applications for its CAR T-cell therapy products in each of the three nations.
- For instance, in June 2022, Bristol Myers Squibb received FDA approval for Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL).
- In February 2022, the US Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 12 months of first line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy to receive a National Comprehensive Cancer Network (NCCN) Category 1 recommendation.

- In February 2022, the FDA approved ciltacabtagene autoleucel (brand name CARVYKTI) for treating adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
- In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) for treating unresectable or metastatic uveal melanoma patients who are HLA-A\*02:01 positive.
- In March 2021, Abecma (idecabtagene vicleucel) was approved by the FDA for treating relapsed or refractory multiple myeloma. The treatment is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy indicated for treating adult patients with refractory multiple myeloma.

Therefore, the increasing number of approvals for T-cell therapies is fueling the market growth.

#### South & Central America T Cell Therapy Market Overview

The South & Central America T-cell therapy market is limited to Brazil as the products are only approved and commercially available in the country. According to the Brazilian Journal of Cancerology, it is estimated that ~704,000 new cases of cancer are expected during 2023-2025. More than 12,000 non-Hodgkin lymphoma (NHL) cases in Brazil are estimated to be diagnosed yearly. The Brazilian Health Regulatory Agency (ANVISA) has approved two CAR T-cell therapies in Brazil: tisagenlecleucel (by Novartis) for pediatric patients and young adults with RR B-cell acute lymphoblastic leukemia (ALL) and adults with relapsed/refractory (RR) diffuse large B-cell lymphoma, and ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM). Moreover, in August 2022, Kite, a Gilead Company, expanded its business by launching operations in Brazil, Singapore, and Saudi Arabia. Kite has submitted regulatory applications for its CAR T-cell therapy products. The rising cases of cancer and lymphoma, and the increasing number of applications and clinical trials for T-cell therapies are expected to boost the demand in the coming years.

#### South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US\$ Mn)

##### South & Central America T Cell Therapy Market Segmentation

The South & Central America T cell therapy market is segmented into modality, therapy type, indication, and country.

Based on modality, the South & Central America T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the South & Central America T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the South & Central America T cell therapy market is bifurcated

into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the South & Central America T cell therapy market is limited to Brazil. Brazil dominated the South & Central America T cell therapy market share in 2022. Bristol-Myers Squibb Co, Gilead Sciences Inc, Janssen Global Services LLC, and Novartis AG are some of the leading companies operating in the South & Central America T cell therapy market.

## Contents

### **1. INTRODUCTION**

- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation

### **2. EXECUTIVE SUMMARY**

- 2.1 Key Insights
- 2.2 South & Central America T Cell Therapy Market, by Country (US\$ Million)

### **3. RESEARCH METHODOLOGY**

- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research

### **4. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - KEY INDUSTRY DYNAMICS**

- 4.1 Market Drivers:
  - 4.1.1 Growing Burden of Cancer Worldwide
  - 4.1.2 Increasing Number of T-Cell Therapy Approvals
- 4.2 Market Restraints
  - 4.2.1 Side-effects of CAR T-Cell Therapy
- 4.3 Market Opportunities
  - 4.3.1 Growing Investment in T-Cell Therapy
- 4.4 Future Trends
  - 4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
- 4.5 Impact Analysis:

### **5. T CELL THERAPY MARKET - SOUTH & CENTRAL AMERICA MARKET ANALYSIS**

- 5.1 South & Central America T Cell Therapy Market Revenue (US\$ Mn), 2022 - 2030

### **6. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY MODALITY.**

## 6.1 Overview

### 6.2 South & Central America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)

## 6.3 Research

### 6.3.1 Overview

### 6.3.2 Research: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US\$ Million)

## 6.4 Commercialized

### 6.4.1 Overview

### 6.4.2 Commercialized: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US\$ Million)

## **7. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY THERAPY TYPE**

## 7.1 Overview

### 7.2 South & Central America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)

## 7.3 CAR T-cell Therapy

### 7.3.1 Overview

### 7.3.2 CAR T-cell Therapy: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US\$ Million)

## 7.4 T-cell Receptor (TCR)-based.

### 7.4.1 Overview

### 7.4.2 T-cell Receptor (TCR)-based: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US\$ Million)

## **8. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY INDICATION**

## 8.1 Overview

### 8.2 South & Central America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)

## 8.3 Hematologic Malignancies

### 8.3.1 Overview

### 8.3.2 Hematologic Malignancies: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US\$ Million)

### 8.3.3 South & Central America T Cell Therapy Market , by Haematological

Malignancies, 2020-2030 (US\$ Million)

8.4 Solid Tumor

8.4.1 Overview

8.4.2 Solid Tumor: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US\$ Million)

## **9. SOUTH & CENTRAL AMERICA T CELL THERAPY MARKET - COUNTRY ANALYSIS**

9.1 Overview

9.1.1 South & Central America T Cell Therapy Market by Country

9.1.1.1 Brazil

9.1.1.1.1 Brazil: South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US\$ Mn)

9.1.1.1.2 Brazil: South & Central America T Cell Therapy Market, by Modality, 2020-2030 (US\$ Million)

9.1.1.1.3 Brazil: South & Central America T Cell Therapy Market, by Therapy Type, 2020-2030 (US\$ Million)

9.1.1.1.4 Brazil: South & Central America T Cell Therapy Market, by Indication, 2020-2030 (US\$ Million)

9.1.1.1.4.1 Brazil: South & Central America T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US\$ Million)

## **10. T CELL THERAPY MARKET-INDUSTRY LANDSCAPE**

10.1 Overview

10.2 Growth Strategies in T Cell Therapy Market

10.3 Organic Growth Strategies

10.3.1 Overview

10.4 Inorganic Growth Strategies

10.4.1 Overview

## **11. COMPANY PROFILES**

11.1 Janssen Global Services LLC

11.1.1 Key Facts

11.1.2 Business Description

11.1.3 Products and Services

11.1.4 Financial Overview

- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
- 11.2 Gilead Sciences Inc
  - 11.2.1 Key Facts
  - 11.2.2 Business Description
  - 11.2.3 Products and Services
  - 11.2.4 Financial Overview
  - 11.2.5 SWOT Analysis
  - 11.2.6 Key Developments
- 11.3 Bristol-Myers Squibb Co
  - 11.3.1 Key Facts
  - 11.3.2 Business Description
  - 11.3.3 Products and Services
  - 11.3.4 Financial Overview
  - 11.3.5 SWOT Analysis
  - 11.3.6 Key Developments
- 11.4 Novartis AG
  - 11.4.1 Key Facts
  - 11.4.2 Business Description
  - 11.4.3 Products and Services
  - 11.4.4 Financial Overview
  - 11.4.5 SWOT Analysis
  - 11.4.6 Key Developments

## **12. APPENDIX**

- 12.1 About Us
- 12.2 Glossary of Terms

## I would like to order

Product name: South & Central America T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

Product link: <https://marketpublishers.com/r/S317869E9B2CEN.html>

Price: US\$ 3,550.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S317869E9B2CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970